Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction

Insulin causes sodium retention and hypoglycaemia and its use is associated with worse outcomes in heart failure (HF) with reduced ejection fraction. We have investigated whether this is also the case in HF with preserved ejection fraction (HFpEF).

[1]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[2]  D. Atar,et al.  Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial , 2018, Circulation. Heart failure.

[3]  S. Solomon,et al.  Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes , 2017, Cardiovascular Drugs and Therapy.

[4]  Anne L. Taylor,et al.  Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial. , 2009, Journal of cardiac failure.

[5]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[6]  W. Paulus,et al.  Molecular and pathophysiological links between heart failure with preserved ejection fraction and type 2 diabetes mellitus , 2018, European journal of heart failure.

[7]  R. Nesto,et al.  Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials , 2007, The Lancet.

[8]  G. Lamas,et al.  Characterization of health‐related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM , 2007, European journal of heart failure.

[9]  Lizy Thottapurathu,et al.  Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial , 2018, Diabetes Care.

[10]  U. S. Department of Health and Human Services FDA Cen Research,et al.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.

[11]  R. Ackermann,et al.  Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. , 2018, JAMA network open.

[12]  Alan Bernjak,et al.  Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk , 2014, Diabetes.

[13]  S. Yusuf,et al.  Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. , 2000, European heart journal.

[14]  Salim Yusuf,et al.  Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[15]  R. McKelvie,et al.  Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction) , 2017, Circulation.

[16]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[17]  Akshay S. Desai,et al.  Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). , 2019, The American journal of cardiology.

[18]  R. Retnakaran,et al.  Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis. , 2018, JACC. Heart failure.

[19]  Deepak L. Bhatt,et al.  Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial , 2014, Circulation.

[20]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[21]  W. Paulus,et al.  Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction. , 2018, JACC. Heart failure.

[22]  Deepak L. Bhatt,et al.  Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. , 2015, Circulation.

[23]  Akshay S. Desai,et al.  Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction , 2016, Circulation. Heart failure.

[24]  Diane M. Miller,et al.  Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. , 2018, Lancet.

[25]  M. Hanefeld,et al.  Hypoglycemia and Cardiovascular Risk: Is There a Major Link? , 2016, Diabetes Care.

[26]  Karl Swedberg,et al.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.

[27]  K. Dickstein,et al.  Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes , 2017, European journal of heart failure.

[28]  A. Quyyumi,et al.  The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction , 2017, Diabetes Care.

[29]  D. Eton,et al.  Comparing Measures to Assess Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. , 2018, JACC. Heart failure.

[30]  Marc P. Bonaca,et al.  Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials , 2019, Circulation.

[31]  R. Doughty,et al.  Ethnic differences in atrial fibrillation in patients with heart failure from Asia-Pacific , 2019, Heart.

[32]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[33]  Rury R Holman,et al.  Real-world studies no substitute for RCTs in establishing efficacy , 2019, The Lancet.

[34]  Akshay S. Desai,et al.  A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF) , 2019, European journal of heart failure.

[35]  S. Yusuf,et al.  Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). , 2018, Circulation.

[36]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.